Expression of p27Kip1 protein in transitional cell carcinoma of the upper urinary tract

Modern Pathology

Volumn 14, Issue 5, 2001, Pages 371-376

  Nakanishi, Kuniaki ^a   Kawai, Toshiaki ^a   Aida, Shinsuke ^a   Kasamatsu, Hiroyasu ^a   Aurues, Takashi ^a   Ikeda, Tomosumi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

P27Kip1 protein; Transitional cell carcinoma; Upper urinary tract

Indexed keywords

CYCLINE; PROTEIN P27; PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL COUNT; CELL CYCLE PROTEINS; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 0035041313     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880320     Document Type: Article

References (37)

1. Kamb A. Cell-cycle regulators and cancer. Trends Genet 1995;11:136-40.
2. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
3. kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-23.
4. Kip1) of cyclin-dependent kinase 4 activation. Cell 1994; 79:487-96.
5. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
6. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
7. Tan P, Cady B, Wanner M, Worland P, Cukor B, MagiGalluzzi C, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res 1997;57:1259-63.
8. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, et al. p27 expression and gastric carcinoma [Letter]. Nat Med 1997;3:593.
9. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
10. Esposito V, Baldi A, DeLuca A, Groger AM, Loda M, Giordano GG, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5.
11. KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res 1998;58:1042-7.
12. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542-8.
13. Yang RM, Naitoh J, Murphy M, Wang H-J, Phillipson J, DeKernion JB, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998; 159:941-5.
14. kip1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 1999;154: 119-25.
15. kip1 and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 1999;155:1129-36.
16. WAF/Cip protein expression in muscle invasive bladder cancer. Oncol Rep 1999;6:687-93.
17. Sidransky D, Von Eschenbech A, Tsai YC, Jones P, Summerhayes I, Marshall F, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252:706-9.
18. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992;52:1393-8.
19. Esrig D, Spruck CH III, Nichols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
20. Nakanishi K, Kawai T, Torikata C. Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract. Hum Pathol 1996;27:1336-40.
21. Nakanishi K, Tominaga S, Kawai T, Torikata C, Aurues T, Ikeda T. Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract. Virchows Archiv 1998; 432:445-50.
22. UICC (International Union Against Cancer). Renal pelvis and ureter. In: Sobin LH, Wittenkind C, editors. TNM classification of malignant tumours. 5th ed. New York: Wiley, 1997:183-6.
23. Murphy WM, Beckwith JB, Farrow GM. Tumors of the kidney, bladder, and related urinary structures. Atlas of tumor pathology. 3rd series, fascicle 11. Washington, DC: Armed Forces Institute of Pathology, 1994:202-19.
24. SAS Institute Inc. The PHREG procedure, version 6. (SAS technical report P-217, SAS/STAT software.) Cary, NC: SAS Institute Inc.; 1991. p. 63.
25. kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol 1998;153:505-13.
26. kip1 expression in endocrine and other tumors. Am J Pathol 1997;150:401-7.
27. KIP1 expression is inversely proportional to the proliferative index. Am J Pathol 1997;151:151-60.
28. KIP1 in multistage colorectal carcinogenesis. Cancer Res 1998;58:114-22.
29. Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol 1998;152:585-90.
30. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
31. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
32. WAF/CIP1 mutations in superficial and invasive transitional cell carcinomas. Oncogene 1996;13:1831-7.
33. Pfister C, Larue H, Moore L, Lacombe L, Veilleux C, Tetu B, et al. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes. Int J Cancer 2000;89:100-4.
34. Lipponen P, Aaltomaa S, Eskelinen M, Ala-Opas M, Kosma V-M. Expression of p21(waf/cip1) protein in transitional cell bladder tumours and its prognostic value. Eur Urol 1998;34: 237-43.
35. Kip1 and apoptosis in human breast cancer. Br J Cancer 1999;79:1572-8.
36. Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci U S A 1998;95:1091-6.
37. Pedram A, Razandi M, Hu R-M, Levin ER. Astrocyte progression from G1 to S phase of the cell cycle depends upon multiple protein interaction. J Biol Chem 1998;273:13966-72.